Sarepta Therapeutics

Rotten tomato splat fruit
Special Reports

Fierce Biotech's Rotten Tomatoes of 2025

Which stories from the year represented strategic missteps, chaotic management or just rotten luck?
Amazing landscapes of Appenzell with impressive rock formations and beautiful lakes

Dyne readies FDA push after DMD exon 51 med excels in trial

Dec 8, 2025 10:50am
Completing steps towards success checkmark on cubes symbolizing progress

Sarepta shares safety update on DM1 RNA med

Nov 24, 2025 4:00pm
sarepta building
Favicon Fierce Pharma

Sarepta, despite key trial flop, will seek full nod for DMD meds

Nov 4, 2025 7:56am
calendar
Favicon Fierce Pharma

Sarepta extends $700M debt to 2030 amid Elevidys uncertainty

Aug 21, 2025 10:52am
Stock exchange concept

Sarepta sells 9M Arrowhead shares for $174M cash

Aug 13, 2025 5:44pm